The Virtual Assessment in Lewy Body Dementia: Pandemic and Beyond – A Series of 3 Webinars in 2021

The COVID-19 pandemic necessitated transition of care to telemedicine due to public health concerns. Those with LBD represent a particularly vulnerable population to the complications of COVID-19 given advanced age […]
Read More

What’s in a Name? It Depends on Who’s Using It

What’s Alzheimer’s disease (AD)? A person off the street will probably describe a memory problem. A healthcare professional will likely say the same. In fact, AD is what happens at […]
Read More

LBDA Partners with Medscape

Despite being a common form of dementia, there is still a tremendous need for more physician education on Lewy body dementia (LBD).  To address this issue, LBDA is proud to […]
Read More

Shifting into Virtual Mode for LBD Research Meetings

In February of 2020 B.C. (before COVID-19), LBDA planned to host/attend 3 day-long meetings related to LBD research in June in Cleveland, OH. And then the pandemic hit. So, we […]
Read More

New Research Definition of Mild Cognitive Impairment with Lewy bodies (MCI-LB)

Most people with Lewy body dementia (LBD) will experience mild changes in thinking; over time, these symptoms, referred to as mild cognitive impairment (MCI), worsen and may become dementia. As […]
Read More

Alzheimer’s and Lewy bodies: When Two Pathologies Collide

DLB is one of two clinical diagnoses under the Lewy body dementia umbrella. When DLB co-occurs with Alzheimer’s disease, a clinical diagnosis is even more difficult to make as symptoms […]
Read More

LBD and Coronavirus: Prevention is the Best Medicine

With all of the news about the coronavirus and the condition “COVID-19,” here are some things that LBD families should keep in mind in the coming weeks and months. This […]
Read More

Loss of Attention May Suggest Faster Progression to Dementia in Very Early LBD

Like other dementias, a person doesn’t develop Lewy body dementia (LBD) overnight. Very mild symptoms worsen over time until medical attention is needed. Sometimes several years pass before these earliest […]
Read More

Biogen’s Aducanumab Clinical Trial Results Revealed

In a stunning reversal last October, pharma giant Biogen announced that its failed Phase 3 clinical trial of aducanemab in people with mild cognitive impairment or mild Alzheimer’s disease didn’t […]
Read More

Positive Results for the HARMONY Clinical Trial of Pimavanserin in Dementia-Related Psychosis

In December ACADIA Pharmaceuticals presented its top-line results from its Phase 3 clinical trial of pimavanserin in people who had dementia-related psychosis. The results had been eagerly awaited; ACADIA stopped […]
Read More

LBDA’s Contributions to the Scientific Community

Throughout the year, LBDA staff have been traveling across the country to promote discussion and awareness of Lewy body dementias in local communities and at national conferences. Here are just a […]
Read More

LBD Caregiver Experience Differs Between Spouses and Adult Children

Being a dementia caregiver can have a negative impact on one’s psychological well-being. But what is specifically known about the impact of LBD caregiving? And how it might differ based […]
Read More

Updated LBD Research Recommendations Published

Every 3 years, a national research summit is held to update research strategies for non-Alzheimer’s dementias. This 2-day national event is one of 3 rotating summits held in response to […]
Read More

National Institutes of Health Award $14 million for LBD Research

People who have LBD plus changes in the brain associated with Alzheimer’s disease tend to have more aggressive disease progression. However, science has not yet explained why these two disease […]
Read More

Rate of Dementia Diagnosis Varies by Clinician Type and Patient Race/Ethnicity

With an aging population and life expectancies on the rise, the number of people with dementia in the U.S. is projected to reach nearly 12 million in 20 years. However, […]
Read More

Treatment Study Halted Early Because of Promising Results

With all the recent news about failed clinical trials for disease-modifying treatments for Alzheimer’s disease, a little encouraging news is timely. ACADIA Pharmaceuticals announced an early end to one of […]
Read More

LBD is the Most Expensive Dementia in America

Dementia is one of the most expensive diseases in the United States, increasing healthcare costs 3 times over those without dementia. Until now, studies on the costs of different dementia […]
Read More

NINDS: Hunting for an LBD Biomarker

Did you know that the National Institute of Neurological Disorders and Stroke (NINDS) plays a leading role in funding research on Lewy body disorders?  Because LBD and Parkinson’s disease share […]
Read More

What Happened In Vegas WON’T Stay in Vegas

Hundreds of LBD researchers, clinicians and families gathered in Las Vegas, NV in June for the 2019 International LBD Conference. Organized by the Cleveland Clinic with assistance from LBDA, it […]
Read More

Imaging Can Aid in DLB Diagnosis Before Dementia Onset

As there is no single symptom pattern that signals the start of dementia with Lewy bodies (DLB), getting a diagnosis is commonly delayed. Finding a definitive medical test that confirms […]
Read More